Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
CA 2894009 C · Owner: Board Of Regents, The University Of Texas System · Inventors: Ran, Sophia; Huang, Xianming; Thorpe, Philip E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antibodies, compositions comprising such antibodies and uses thereof in the , treatment of diseases such as cancer are described, in which the antibodies are observed to bind to a phosphatidylserine (PS)-coated ELISA , plate in an ELISA conducted in the presence of 10% serum. Hybridomas and host cells producing such , antibodies, as well as nucleic acids and expression vectors encoding such antibodies are also provided. , Antibodies described herein include antibody 3G4 deposited as ATCC Accession , Number PTA 4545 and , chimeric 3G4 antibodies comprising human antibody constant regions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 15, 2003 and granted December 6, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 15, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 15, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.